JHP Pharmaceuticals announced that the FDA has approved its rapidly-mixing formulation of Dantrium IV (dantrolene sodium for injection), designed to save time and effort during the emergency treatment of malignant hyperthermia (MH). Dantrium IV now reconstitutes in approximately 20 seconds, which is 4 times faster than before, with noticeably less vigorous shaking required to complete the reconstitution process. Additionally, the Dantrium IV vial now features an easy-to-open flip-off vial cap and an easy-to-identify red vial cap and red vial label.
Dantrium IV is indicated, along with supportive measures, for managing fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Dantrium IV is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of MH in individuals judged to be MH susceptible.
For more information call (866) 923-2547 or visit www.jhppharma.com.